1045 Results for "

Gastric

" in MedChemExpress (MCE) Product Catalog:

Products (1045)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

154

Erlotinib Hydrochloride

154 Publications Verification

Cat. No.: HY-12008

CAS No.: 183319-69-9

Purity: 99.94%

Synonyms: CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride

Target:

EGFR OAT ERK GSK-3 β-catenin

Research Areas:

Endocrinology Cancer

Erlotinib (CP-358774) Hydrochloride is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib Hydrochloride also acts as a substrate and inhibitor of OATP2B1, with an IC₅₀ of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib Hydrochloride blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib Hydrochloride inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib Hydrochloride is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib Hydrochloride can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

154

Erlotinib

154 Publications Verification

Cat. No.: HY-50896

CAS No.: 183321-74-6

Synonyms: CP-358774; NSC 718781; OSI-774

Target:

EGFR OAT ERK GSK-3 β-catenin

Research Areas:

Endocrinology Cancer

Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC₅₀ of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

138

Alpelisib

138 Cited Publications

Cat. No.: HY-15244

CAS No.: 1217486-61-7

Purity: 99.88%

Synonyms: BYL-719

Target:

PI3K Apoptosis

Research Areas:

Infection Neurological Disease Metabolic Disease Cancer

Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

138

Alpelisib hydrochloride

138 Cited Publications

Cat. No.: HY-15244A

CAS No.: 1584128-91-5

Synonyms: BYL-719 hydrochloride

Target:

PI3K Apoptosis

Research Areas:

Infection Neurological Disease Metabolic Disease Cancer

Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

123

EIPA hydrochloride

123 Cited Publications

Cat. No.: HY-101840A

CAS No.: 1345839-28-2

Purity: 98.31%

Synonyms: L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride

Target:

TRP Channel Autophagy COX Prostaglandin Receptor Na+/H+ Exchanger (NHE)

Research Areas:

Inflammation/Immunology Cancer

EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na ⁺/H ⁺-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

123

EIPA

123 Cited Publications

Cat. No.: HY-101840

CAS No.: 1154-25-2

Purity: 99.73%

Synonyms: L593754; MH 12-43; Ethylisopropylamiloride

Target:

TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE)

Research Areas:

Inflammation/Immunology Cancer

EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA also enhances autophagy by inhibiting Na ⁺/H ⁺-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

117

Afatinib

117 Cited Publications

Cat. No.: HY-10261

CAS No.: 850140-72-6

Purity: 99.92%

Synonyms: BIBW 2992

Target:

EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK

Research Areas:

Cancer

Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

117

Afatinib dimaleate

117 Cited Publications

Cat. No.: HY-10261A

CAS No.: 850140-73-7

Purity: 99.74%

Synonyms: BIBW 2992MA2

Target:

EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK

Research Areas:

Cancer

Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

Compare